Pluri Inc.

PLUR

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001158780


None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $24.9M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, short runway, thin data; fortr... not computable: distress
Inputs computable	6 of 14
Graded from	filings received through Sep 10, 2026 58 days before the rescan; latest periodic filing 10-K received Sep 10, 2026
Last close	$1.24 2026-11-03; market equity $15.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Sep 10, 2026

leveraging our proprietary 3D cell expansion platform, which is supported by an in-house, industrial-scale cell manufacturing facility and operates in accordance with Good Manufacturing Practice ("GMP") standards on a self-declared basis. Our platform is designed to enable scalable, cost-efficient and reproducible expansion of human, plant and animal cells and supports cell-based products, services, therapeutics and related technologies across two primary application areas: (i) Human Health and Longevity and (ii) Foodtech and Bio-Farming. on May 11, 2001. Pluri Inc. has a wholly owned subsidiary, Pluri Biotech Ltd.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 61.1						
Gross profitability	1.8%	32.3%		89.0	365	2026-06-30
Return on invested capital	not computable	9.3%				

required facts have no common fiscal period end

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(13.3%)	(6.6%)	33.2	802	2026-06-30
Gross margin stability, five years	not computable	2.8 pts			
five consecutive annual gross margins are required					
Solvency, sleeve percentile 96.7					
Twelve-month failure probability	not computable	0.08%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	not computable	(0.37)			
one or more required annual facts are missing					
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-06-30; latest annual assets end 2026-06-30					
Current ratio	0.27x	2.94x	96.7	828	2026-06-30
Growth and financing, sleeve percentile 58.0					
Revenue growth, three-year compound	52.4%	10.0%	13.1	412	2026-06-30
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	(21.2%)	2.2%	85.3	696	2026-06-30
Net share issuance, one year	51.4%	2.5%	75.5	630	2026-09-09

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 51.4%
Short runway	cash runway is 2.2 months
Thin data	6 of 14 grade factors are computable; minimum is 7
Fortress balance sheet	cash minus debt is 7,009,000 USD; Altman Z is not used

What the price implies

at the 2026-11-03 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(74.4%)	(2.1%)	7
Distance from 52-week high	(72.2%)	(30.5%)	12
EBIT to enterprise value	(192.1%)	(1.5%)	4
Free cash flow yield	(132.6%)	(1.0%)	5
Book value to price	(1.51)	0.29	1
Sales to price	0.07	0.30	20
Composite equity issuance, five years	112.7%	21.4%	81
Relative strength against the sector, log excess return	(1.53)	(0.19)	7

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-06-30	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$3.5M
Operating cash flow, four quarters	-$19.6M
Months of runway	2.2
Days since last periodic filing	58 (10-K received Sep 10, 2026)
Median daily dollar volume, 63 sessions	$19,235

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$453,000	2026-06-30	2026-09-10	10-K	26-098862
2	assets	us-gaap:Assets	$24.9M	2026-06-30	2026-09-10	10-K	26-098862
3	net income	us-gaap:NetIncomeLoss	-$23.8M	2026-06-30	2026-09-10	10-K	26-098862
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$19.6M	2026-06-30	2026-09-10	10-K	26-098862
5	assets	us-gaap:Assets	$38.7M	2025-06-30	2026-09-10	10-K	26-098862
6	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$1.3M	2020-06-30	2020-09-10	10-K	20-026105
7	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$8.3M	2020-06-30	2021-09-13	10-K	21-047664
8	operating income	us-gaap:OperatingIncomeLoss	-$29.5M	2020-06-30	2021-09-13	10-K	21-047664
9	depreciation amortization	us-gaap:Depreciation	$1.6M	2020-06-30	2021-09-13	10-K	21-047664
10	operating income	us-gaap:OperatingIncomeLoss	-$27.2M	2023-06-30	2024-09-18	10-K	24-079861
11	interest expense	us-gaap:InterestExpense	$843,000	2023-06-30	2023-09-12	10-K	23-076079
12	current assets	us-gaap:AssetsCurrent	$8.7M	2026-06-30	2026-09-10	10-K	26-098862
13	current liabilities	us-gaap:LiabilitiesCurrent	$32.7M	2026-06-30	2026-09-10	10-K	26-098862
14	revenue	us-gaap:Revenues	$1.0M	2026-06-30	2026-09-10	10-K	26-098862
15	revenue	us-gaap:Revenues	$1.3M	2025-06-30	2026-09-10	10-K	26-098862
16	revenue	us-gaap:Revenues	$326,000	2024-06-30	2025-09-17	10-K	25-088578
17	revenue	us-gaap:Revenues	$287,000	2023-06-30	2024-09-18	10-K	24-079861
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$633,000	2026-06-30	2026-09-10	10-K	26-098862
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$18.2M	2025-06-30	2026-09-10	10-K	26-098862
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.6M	2025-06-30	2026-09-10	10-K	26-098862
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$18.0M	2024-06-30	2025-09-17	10-K	25-088578
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$323,000	2024-06-30	2025-09-17	10-K	25-088578
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$22.9M	2023-06-30	2024-09-18	10-K	24-079861
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$262,000	2023-06-30	2024-09-18	10-K	24-079861
25	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$511,000	2026-06-30	2026-09-10	10-K	26-098862
26	operating income	us-gaap:OperatingIncomeLoss	-$24.9M	2026-06-30	2026-09-10	10-K	26-098862
27	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$25.4M	2026-06-30	2026-09-10	10-K	26-098862
28	income tax	us-gaap:IncomeTaxExpenseBenefit	-$25,000	2026-06-30	2026-09-10	10-K	26-098862
29	current assets	us-gaap:AssetsCurrent	$22.1M	2025-06-30	2026-09-10	10-K	26-098862
30	current liabilities	us-gaap:LiabilitiesCurrent	$32.3M	2025-06-30	2026-09-10	10-K	26-098862
31	assets	us-gaap:Assets	$39.5M	2024-06-30	2025-09-17	10-K	25-088578
32	assets	us-gaap:Assets	$50.8M	2023-06-30	2024-09-18	10-K	24-079861
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,344,736	2026-09-09	2026-09-10	10-K	26-098862
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,155,948	2025-09-16	2025-09-17	10-K	25-088578

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.